This COMPREHENSIVE GERMLINE PANEL analyzes 88 clinically-relevant genes that are associated with genetic disorders, including most hereditary cancers.
Appropriate interpretation of results together with a genetic counselor can help clinicians to provide guidance to patients regarding clinical risk and genetic causes of diseases. The assay detects single- and multi-nucleotide substitutions and small insertions and deletions in coding regions and exon-intron junctions, as well as large genomic rearrangements of the target genes. The assay provides >1500X average coverage at the targeted genomic regions of the tested genes.
Prostate cancer
PROSTATENOW™ is a germline test for people with prostate cancer. This test can be used to predict prognosis among men with localized prostate cancer, predict therapeutic responses for advanced patients, and predict cancer risk among unaffected men.
Learn more
Breast cancer
There is an increased likelihood of a BRCA1 or BRCA2 mutation in patients with certain personal and family history characteristics and various clinical criteria. BRCANOW® is a Next-Gen Sequencing (NGS)-based assay using a state-of-the-art platform to detect whether or not a mutation is present.
Learn more
Colorectal cancer
LYNCHNOW® is a cost-effective, screening tool that rapidly detects mutations that cause Lynch syndrome.
Learn more
We're here to guide you through the process.
Part of 88 GENE PANEL includes genetic counseling to walk you through our process and test results, along with any lifestyle or treatment alternatives depending on your results.